Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:ECOR NASDAQ:POAI NASDAQ:TMDIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.58-1.9%$2.40$1.31▼$5.00$32.81M1.6153,213 shs5,703 shsECORelectroCore$4.84+0.2%$6.01$4.16▼$19.49$36.70M0.36125,150 shs27,388 shsPOAIPredictive Oncology$1.02+9.3%$0.84$0.55▼$3.06$11.11M1.371.76 million shs168,232 shsTMDIFTitan Medical$0.36$0.34$0.03▼$1.00$41.28M1.2674,785 shs222 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+0.38%-0.42%+3.14%+68.59%-47.50%ECORelectroCore+1.90%-1.83%-7.82%-4.92%-20.82%POAIPredictive Oncology-1.79%-2.91%+8.98%+1.41%+3.67%TMDIFTitan Medical0.00%+7.57%+11.32%+39.98%+990.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.58-1.9%$2.40$1.31▼$5.00$32.81M1.6153,213 shs5,703 shsECORelectroCore$4.84+0.2%$6.01$4.16▼$19.49$36.70M0.36125,150 shs27,388 shsPOAIPredictive Oncology$1.02+9.3%$0.84$0.55▼$3.06$11.11M1.371.76 million shs168,232 shsTMDIFTitan Medical$0.36$0.34$0.03▼$1.00$41.28M1.2674,785 shs222 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies+0.38%-0.42%+3.14%+68.59%-47.50%ECORelectroCore+1.90%-1.83%-7.82%-4.92%-20.82%POAIPredictive Oncology-1.79%-2.91%+8.98%+1.41%+3.67%TMDIFTitan Medical0.00%+7.57%+11.32%+39.98%+990.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.00Buy$11.50345.74% UpsideECORelectroCore 3.00Buy$25.50426.86% UpsidePOAIPredictive Oncology 2.00HoldN/AN/ATMDIFTitan Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest POAI, TMDIF, ECOR, and CLGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/21/2025CLGNCollPlant BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/20/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$2.40M13.66N/AN/A$1.18 per share2.19ECORelectroCore$27.70M1.32N/AN/A$1.13 per share4.28POAIPredictive Oncology$1.62M6.86N/AN/A($0.03) per share-34.00TMDIFTitan Medical$17.63M2.34$18.10 per share0.02$1.05 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$16.61M-$1.13N/AN/AN/A-541.34%-94.08%-68.62%11/3/2025 (Estimated)ECORelectroCore-$11.89M-$1.62N/AN/AN/A-47.84%-221.93%-69.17%11/12/2025 (Estimated)POAIPredictive Oncology-$12.66M-$3.05N/AN/AN/A-587.31%-722.01%-167.23%11/11/2025 (Estimated)TMDIFTitan Medical$6.95M$0.05N/A∞N/AN/A-82.31%-51.47%N/ALatest POAI, TMDIF, ECOR, and CLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/20/2025Q2 2025CLGNCollPlant Biotechnologies$0.29-$0.28-$0.57-$0.28$8.91 million$0.18 million8/13/2025Q2 2025POAIPredictive Oncology-$0.09-$0.22-$0.13-$0.23$1.50 million$0.00 million8/6/2025Q2 2025ECORelectroCore-$0.32-$0.35-$0.03-$0.44$7.24 million$7.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A4.604.40ECORelectroCoreN/A1.100.95POAIPredictive OncologyN/A0.320.31TMDIFTitan MedicalN/A3.733.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%ECORelectroCore26.74%POAIPredictive Oncology9.04%TMDIFTitan Medical0.03%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%ECORelectroCore13.80%POAIPredictive Oncology3.44%TMDIFTitan Medical0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableECORelectroCore507.58 million6.54 millionNot OptionablePOAIPredictive Oncology3010.89 million10.52 millionNot OptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionablePOAI, TMDIF, ECOR, and CLGN HeadlinesRecent News About These CompaniesTitan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare StaffingApril 29, 2025 | businesswire.comTitan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing ServicesApril 29, 2025 | businesswire.comTitan MRI acquires High Field MRI, expanding Titan MRI's service to North Central FloridaDecember 3, 2024 | msn.comAttack on Titan movie release date, trailer, changes, and everything else we know about The Last AttackNovember 6, 2024 | gamesradar.comGConavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business CombinationOctober 11, 2024 | globenewswire.comTitan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the TransactionOctober 8, 2024 | globenewswire.comTitan Announces Resignations of DirectorsOctober 2, 2024 | globenewswire.comTitan Reports Voting Results from 2023 Annual General and Special MeetingSeptember 30, 2024 | globenewswire.comTitan Medical begins process to move to the TSX Venture ExchangeSeptember 30, 2024 | globenewswire.comConavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and ConaviSeptember 26, 2024 | globenewswire.comProxy Deadline Thursday September 26, 2024September 25, 2024 | globenewswire.comProxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 19, 2024 | globenewswire.comA key employee says the Titan sub tragedy could have been preventedSeptember 18, 2024 | postregister.comPIndependent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 16, 2024 | globenewswire.comTitan Announces Conavi Medical to Present Overview at Titan Q&A SessionSeptember 16, 2024 | globenewswire.comTitan Announces Q&A Session with ShareholdersSeptember 9, 2024 | globenewswire.comTitan Announces Filing of the Management Information Circular.September 6, 2024 | globenewswire.comTitan Medical | Morning BlendSeptember 3, 2024 | msn.comTitan Medical Inc. (QTNA.SG)August 24, 2024 | finance.yahoo.comTitan Medical Reports Operating and Financial Results for the Second Quarter 2024August 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesFree Cash Flow Boom Keeps Microsoft Ahead of the PackBy Chris Markoch | August 29, 2025Semtech: Bullish Market Forces Come Into Alignment for This StockBy Thomas Hughes | August 27, 2025Zscaler Shares Can Hit a Fresh High Before Year-EndBy Thomas Hughes | September 3, 2025Royal Caribbean Earnings Beat Fuels Strong 2025 OutlookBy Jeffrey Neal Johnson | August 22, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025POAI, TMDIF, ECOR, and CLGN Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.58 -0.05 (-1.71%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.electroCore NASDAQ:ECOR$4.84 +0.01 (+0.21%) Closing price 04:00 PM EasternExtended Trading$4.82 -0.02 (-0.41%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Predictive Oncology NASDAQ:POAI$1.02 +0.09 (+9.32%) Closing price 04:00 PM EasternExtended Trading$1.00 -0.02 (-1.96%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Titan Medical NASDAQ:TMDIF$0.36 0.00 (0.00%) As of 09/12/2025Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
